


## **Supplementary table and figures**

### **Performance of disk diffusion and MIC gradient tests in tigecycline susceptibility testing of enterococci: A Nordic multicentre study**


Ingeborg Mathiesen, Bjørg Christina Haldorsen, Lars Småbrekke, Erika Matuschek, Frode Skjold, Barbara Juliane Holzkecht, Kristján Orri Helgason, Heikki Ilmavirta, Gunnar Kahlmeter, Arnfinn Sundsfjord, Kristin Hegstad on behalf of the NordicAST 2023 LRE-TRE Study Group

**Table S1** Genome identification names and sequence accession numbers.

| <b>Strain</b> | <b>Genome ID</b> | <b>BioProject</b> | <b>Accession no</b> |
|---------------|------------------|-------------------|---------------------|
| 1             | KresLRE-1        | PRJEB64173        | ERS28304592         |
| 2             | KresLRE-2        | PRJEB64173        | ERS18926080         |
| 3             | KresLRE-4        | PRJEB64173        | ERS18926086         |
| 4             | 51271052         | PRJEB64173        | ERS28304591         |
| 5             | KresLRE-8        | PRJEB64173        | ERS18926095         |
| 6             | KresVRE0169      | PRJEB64173        | ERS28304600         |
| 7             | KresLRE-14       | PRJEB64173        | ERS18926077         |
| 8             | 51271223         | PRJNA858233       | GCA_032190475.1     |
| 9             | KresLRE-17       | PRJEB64173        | ERS28304593         |
| 10            | KresLRE-20       | PRJEB64173        | ERS28304594         |
| 11            | KresLRE-25       | PRJEB64173        | ERS28304595         |
| 12            | KresLRE-30       | PRJEB64173        | ERS28304596         |
| 13            | KresLRE-35       | PRJEB64173        | ERS18926085         |
| 14            | KresLRE-37       | PRJEB64173        | ERS28304597         |
| 15            | 51271924         | PRJNA858233       | GCA_032027865.1     |
| 16            | KresVRE0042      | PRJEB64173        | ERS16600493         |
| 17            | 51271927         | PRJNA858233       | GCA_032948735.1     |
| 18            | KresLRE-51       | PRJEB64173        | ERS28304598         |
| 19            | KresTRE0001      | PRJEB64173        | ERS15990992         |
| 20            | KresLRE-103      | PRJEB64173        | ERS28304599         |



**Fig. S1** Distribution of tigecycline disk diffusion inhibition zone diameters for *E. faecalis* ATCC 29212 by the disk manufacturer. Bar chart showing the inhibition zone diameters (mm) distribution for quality control testing of *E. faecalis* ATCC 29212 using the EUCAST disk diffusion method with tigecycline (15 µg) (n=44). Results are stratified by disk manufacturer (BD, Mast, Oxoid, and Rosco). The target inhibition zone diameter is 23 mm, with an acceptable range of 20–26 mm. The x-axis represents the inhibition zone diameter in millimetres, while the y-axis indicates the number of laboratories reporting each measurement.



**Fig. S2** Distribution of MIC values for *E. faecalis* ATCC 29212 in tigecycline gradient testing by the manufacturer. Bar chart illustrating the distribution of minimum inhibitory concentration (MIC) values (mg/L) for *E. faecalis* ATCC 29212 using tigecycline gradient test method (n=40). Results are stratified by manufacturer (Etest/bioMérieux and MTS/Liofilchem). The target MIC is 0.064 mg/L, with an acceptable range of 0.032–0.125 mg/L. The x-axis shows the MIC values, while the y-axis indicates the number of laboratories reporting each value.